索格列净对2型糖尿病合并CKD患者肾脏结局的影响:SCORED试验二次分析
SCORED试验二次分析纳入10,584例2型糖尿病合并CKD患者,利用实验室eGFR数据评估索格列净对肾脏复合终点的影响。索格列净降低肾脏复合终点风险(HR 0.62,95%CI 0.48-0.82,P<0.001)及心肾复合终点风险(HR 0.77,95%CI 0.65-0.91,P=0.0023),AKI发生率组间相似。
要点
- 索格列净降低心肾复合终点风险达23%(HR 0.77)。
- 不同eGFR下降阈值下结果一致,AKI发生率无差异。
核心结论
- 在2型糖尿病合并CKD患者中,索格列净降低肾脏复合终点及心肾复合终点风险。
研究设计与样本
- SCORED为多中心随机试验,纳入10,584例2型糖尿病合并CKD患者,比较索格列净与安慰剂。
- 本分析为探索性二次分析,使用实验室eGFR数据推导肾脏复合终点中的eGFR组分。
主要发现
- 肾脏复合终点(eGFR持续下降≥50%、eGFR<15 ml/min/1.73m²、透析或肾移植)索格列净组87例(1.6%),安慰剂组136例(2.6%),HR 0.62(95%CI 0.48-0.82),P<0.001。
- 心肾复合终点(上述复合终点+心血管或肾脏死亡)索格列净组239例(4.5%),安慰剂组306例(5.7%),HR 0.77(95%CI 0.65-0.91),P=0.0023。
- 使用不同eGFR下降阈值及仅纳入肾脏死亡时结果一致(均P<0.01)。
- AKI发生率在治疗组间相似。
临床怎么用
- 对于2型糖尿病合并CKD患者,索格列净可考虑用于降低肾脏及心肾复合终点风险。
局限性
- 本分析为探索性二次分析,使用实验室eGFR数据而非完整病例报告表数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the initial analysis of the Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk (SCORED) trial, because of early trial termination and suspension of adjudication, reconciliation of eGFR laboratory data and case report forms had not been completed. This resulted in a small number of kidney composite events and a nominal effect of sotagliflozin versus placebo on this outcome. This exploratory analysis uses laboratory eGFR data, regardless of case report form completion, to assess the effects of sotagliflozin on the predefined kidney composite end point in the SCORED trial and additional cardiorenal composite end points. METHODS: SCORED was a multicenter, randomized trial evaluating cardiorenal outcomes with sotagliflozin versus placebo in 10,584 patients with type 2 diabetes and CKD. This exploratory analysis used laboratory data to derive the eGFR components and case report form data for the non-laboratory-defined components that together made up the kidney and cardiorenal composites. AKI was also assessed in this dataset. RESULTS: Using laboratory data, 223 events were identified, and sotagliflozin reduced the risk of the composite of first event of sustained ≥50% decline in eGFR, eGFR <15 ml/min per 1.73 m 2 , dialysis, or kidney transplant with 87 events (1.6%) in the sotagliflozin group and 136 events (2.6%) in the placebo group (hazard ratio [95% confidence interval], 0.62 [0.48 to 0.82]), P < 0.001). Sotagliflozin reduced the risk of a cardiorenal composite end point defined as the abovementioned composite plus cardiovascular or kidney death with 239 events (4.5%) in the sotagliflozin group and 306 events (5.7%) in the placebo group (hazard ratio [95% confidence interval], 0.77 [0.65 to 0.91], P = 0.0023). The results were consistent when using different eGFR decline thresholds and when only including kidney death in composites (all P < 0.01). The incidence of AKI was similar between treatment groups. CONCLUSIONS: In this exploratory analysis using the complete laboratory dataset, sotagliflozin reduced the risk of kidney and cardiorenal composite end points in patients with type 2 diabetes and CKD. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: ClinicalTrials.gov Identifier: NCT03315143 .
引用
- Sridhar VS, Bhatt DL, Odutayo A, et al. Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD: A Secondary Analysis of the SCORED Trial. Clin J Am Soc Nephrol. 2024. PMID: 38277468. doi:10.2215/CJN.0000000000000414
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。